Neurogastrx Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Private

  • Employees
  • 12

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $80M

  • Investors
  • 7

Neurogastrx General Information

Description

Developer of specialty therapies designed to treat gastrointestinal disorders affecting the enteric nervous system. The company's therapies address the unmet needs of functional and motility gastrointestinal disorders affecting gut contractions, sensation, and the brain-gut axis, enabling the medical community to satisfy the unmet patient needs and disease burden.

Contact Information

Website
neurogastrx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 500 Unicorn Park Drive
  • Suite 300
  • Woburn, MA 01801
  • United States
+1 (781)
Primary Industry
Therapeutic Devices
Other Industries
Pharmaceuticals
Vertical(s)
Corporate Office
  • 500 Unicorn Park Drive
  • Suite 300
  • Woburn, MA 01801
  • United States
+1 (781)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Neurogastrx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series B) 12-Jul-2021 $80M Completed Clinical Trials - Phase 2
2. Later Stage VC (Series A) 01-Aug-2018 Completed Clinical Trials - Phase 2
1. Seed Round 12-Sep-2016 $2.75M $2.75M Completed Clinical Trials - Phase 2
To view Neurogastrx’s complete valuation and funding history, request access »

Neurogastrx Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A
Seed 1,363,633 $0.000100 6% $0.55 $0.55 1x $0.55 0.67%
To view Neurogastrx’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Neurogastrx Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of specialty therapies designed to treat gastrointestinal disorders affecting the enteric nervous system. The
Therapeutic Devices
Woburn, MA
12 As of 2025

Waltham, MA
 

Bagsvaerd, Denmark
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Neurogastrx Competitors (11)

One of Neurogastrx’s 11 competitors is Alcresta Therapeutics, a Private Equity-Backed company based in Waltham, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Alcresta Therapeutics Private Equity-Backed Waltham, MA
Novo Nordisk Corporation Bagsvaerd, Denmark
Aries Pharmaceuticals Corporation San Diego, CA
Pfizer Pakistan Corporation Karachi, Pakistan
Ardelyx Formerly VC-backed Waltham, MA
You’re viewing 5 of 11 competitors. Get the full list »

Neurogastrx Patents

Neurogastrx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026080594-A1 Metopimazine and its salts as adjunct therapy with glp-1 agonists Pending 09-Oct-2024
EP-4271385-A1 Methods of metabolizing metopimazine and its salts Inactive 29-Dec-2020
EP-4271385-A4 Methods of metabolizing metopimazine and its salts Inactive 29-Dec-2020
US-20240156832-A1 Methods of metabolizing metopimazine and its salts Inactive 29-Dec-2020
WO-2022146970-A1 Methods of metabolizing metopimazine and its salts Inactive 29-Dec-2020 A61K31/5415
To view Neurogastrx’s complete patent history, request access »

Neurogastrx Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Neurogastrx Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Marshall Wace Hedge Fund Minority
RTW Investments Hedge Fund Minority
Samsara BioCapital Venture Capital Minority
Vivo Capital Venture Capital Minority
5AM Ventures Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

Neurogastrx FAQs

  • When was Neurogastrx founded?

    Neurogastrx was founded in 2012.

  • Where is Neurogastrx headquartered?

    Neurogastrx is headquartered in Woburn, MA.

  • What is the size of Neurogastrx?

    Neurogastrx has 12 total employees.

  • What industry is Neurogastrx in?

    Neurogastrx’s primary industry is Therapeutic Devices.

  • Is Neurogastrx a private or public company?

    Neurogastrx is a Private company.

  • What is the current valuation of Neurogastrx?

    The current valuation of Neurogastrx is .

  • What is Neurogastrx’s current revenue?

    The current revenue for Neurogastrx is .

  • How much funding has Neurogastrx raised over time?

    Neurogastrx has raised $128M.

  • Who are Neurogastrx’s investors?

    Marshall Wace, RTW Investments, Samsara BioCapital, Vivo Capital, and 5AM Ventures are 5 of 7 investors who have invested in Neurogastrx.

  • Who are Neurogastrx’s competitors?

    Alcresta Therapeutics, Novo Nordisk, Aries Pharmaceuticals, Pfizer Pakistan, and Ardelyx are some of the 11 competitors of Neurogastrx.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process